Avalo Therapeutics, Inc. (AVTX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenues, net | - | 249 | - | |
| Research and development | 14,074 | 9,538 | 4,601 | |
| General and administrative | 5,242 | 4,286 | 4,528 | |
| Cost of product sales | - | -714 | 343 | |
| Acquired in-process research and development | - | - | 103 | |
| Total operating expenses | 19,316 | 13,110 | 9,575 | |
| Loss from operations | -19,316 | -12,861 | -9,575 | |
| Change in fair value of derivative liability | - | -1,100 | -5,040 | |
| Other expense, net | -5 | -5 | - | |
| Interest income, net | 1,102 | 964 | 1,039 | |
| Change in fair value of warrant liability | - | -36,025 | -112,046 | |
| Private placement transaction costs | - | - | - | |
| Change in fair value of derivative liability | 2,530 | - | - | |
| Excess of initial warrant fair value over private placement proceeds | - | - | - | |
| Total other (expense) income, net | -1,433 | 35,884 | 108,045 | |
| (loss) income before taxes | -20,749 | 23,023 | 98,470 | |
| Income tax expense | 16 | -14 | 7 | |
| Net (loss) income | -20,765 | 23,037 | 98,463 | |
| Unrealized loss on investments, net | -34 | - | - | |
| Comprehensive (loss) income | -20,799 | 23,037 | 98,463 | |
| Net (loss) income per share of common stock - basic (in dollars per share) | -1.92 | 0.98 | 4.21 | |
| Net loss per share of common stock - diluted (in dollars per share) | -1.92 | -2.83 | -14.07 | |
| Weighted average common shares outstanding, basic (in shares) | 10,829,760 | 5,546,257 | 1,034,130 | |
| Weighted average common shares outstanding, diluted (in shares) | 10,829,760 | 10,784,037 | 7,653,302 | |